Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LAVAL, QC, June 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that D. Robert Hale has resigned from his role as an independent director of the Company's Board of Directors ("Board") to focus on other business obligations related to his firm, ValueAct Capital ("ValueAct"), a shareholder of the Company.

Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors

LAVAL, QB and ST. PAUL, Minn., June 8, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that its affiliate has entered into an agreement with Lochan LLC ("Lochan") to develop the next-generation of Bausch + Lomb's eyeTELLIGENCE™ clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed to allow surgeons to seamlessly integrate all aspects of the cataract, retinal and refractive surgery processes to maximize their overall practice efficiency. The companies expect to launch the initial phase of this next-generation software in 2022.

Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software

LAVAL, Quebec, June 7, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offer (the "Tender Oﬀer"), to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the "Notes"), as well as the anticipated early settlement date for the Tender Offer on June 8, 2021 (the "Early Settlement Date"). The terms and conditions of the Tender Offer are described in an Oﬀer to Purchase dated May 24, 2021 (as it may be amended or supplemented from time to time, the "Offer to Purchase").

Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 13.8% Since Last Earnings Report?

Bumble

Beyond Meat

Looking for huge winners over the long run? Here are three top picks.

The 3 Best Stocks to Buy for Summer 2021

Bausch Health Companies Inc. (BHC) CEO Joseph Papa Presents at Jefferies Healthcare Conference Call Transcript

Clearside Biomedical

PDUFA Action Date Is October 30 , 2021 LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™1 (triamcinolone acetonide suprachoroidal injectable suspension).

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

Organizations Also Launch Social Media Donation Program to Support Prevent Blindness and Broaden Patients' Access to Cataract Surgery and Care During June's Cataract Awareness Month LAVAL, QC and CHICAGO, June 1, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Prevent Blindness, the nation's oldest volunteer eye health non-profit organization, today announced that they are joining forces during Cataract Awareness Month in June to educate the public and raise awareness of the symptoms, causes and treatment options for cataracts, the leading cause of vision loss in the United States and the leading cause of blindness worldwide.1 Treatment options include cataract surgery, which is one of the most effective and common medical procedures with an overall success rate of 99 percent when performed in appropriate settings.2 Approximately four million cataract surgeries are performed each year in the United States.3 However, anxiety around the operation itself is experienced by many cataract surgery patients leading up to the procedure.4 "As a leader in eye health, Bausch + Lomb is proud to raise awareness of this incredibly common eye condition and its treatment options, particularly following the interruptions seen in routine medical healthcare as a result of the pandemic," said Joe Gordon, U.S. president, Bausch + Lomb. "We share this commitment with Prevent Blindness, an incredible organization that goes to extreme lengths to help people, and we look forward to working with them to provide people affected by cataracts with information and resources to support their care.

Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month

LAVAL, Quebec, May 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations. Bausch Health will redeem $100 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2025, CUSIP Nos.

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

Bausch Health Companies Inc. (BHC) Management Presents at Barclays High Yield Bond Conference (Transcript)

LAVAL, QC, May 25, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Joseph C. Papa, chairman and chief executive officer; Sam Eldessouky, senior vice president and corporate controller; and Arthur J.

Bausch Health Announces Participation At The Jefferies Healthcare Conference

LAVAL, Quebec, May 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today that it has commenced a cash tender oﬀer (the "Tender Offer") to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the "Notes"). The terms and conditions of the Tender Oﬀer are described in an Oﬀer to Purchase dated May 24, 2021 (as it may be amended or supplemented from time to time, the "Offer to Purchase").

Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024

LAVAL, Quebec, May 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.6 billion aggregate principal amount of new senior secured notes due 2028 (the "Notes"). The proceeds from the offering of the Notes, along with cash on hand, are expected to be used to fund the repurchase of $1.6 billion aggregate principal amount of the Company's existing 7.00% Senior Secured Notes due 2024 (the "2024 Notes") pursuant to the Company's concurrently announced tender offer (the "Tender Offer") and to pay related fees, premiums and expenses.

Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes

BHC stock could jump higher in anticipation of the upcoming spin-off. Markets not deterred by high debt load.

Bausch Health: Buy Ahead Of Bausch + Lomb Spin-Off

Goldman Sachs

Bausch Health Companies Inc. (BHC) Presents at Goldman Sachs 6th Annual Credit and Leveraged Finance Conference (Transcript)

TRULANCE® (plecanatide) ePoster Will be Honored as Poster of Distinction LAVAL, QC, May 17, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced four scientific poster presentations featuring data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) to be shared at Digestive Disease Week® (DDW) 2021, which takes place virtually May 21-23, 2021. The posters will be accessible on DDW's ePosters and ePapers online portal beginning Friday, May 21, 2021.

Salix Will Feature New Data At Digestive Disease Week® 2021

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

ACI Worldwide

Lionheart Holdings

Danone SA

Delek US Hlds

Elanco Animal Health Inc

FirstEnergy

Forward Air

Intel

Kohl's

Prudential

Exxon Mobil

Xerox

Poorly managed companies may not be on everyone's radar, but they're top picks for activist investors looking to boost shareholder value.

13 Stocks Activist Investors Are Buying

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics appoints Brent Saunders, Robert Ruffolo, Ph.D., and Robin Steele to its Board of Directors

OcuTerra Strengthens Board of Directors with Three New Key Appointments

Bausch Health Companies' (BHC) CEO Joe Papa on Q1 2021 Results - Earnings Call Transcript

The company's mixed Q1 results are partially to blame.

Why Bausch Health Stock Is Falling Today

Albertsons Companies

Bausch Health and Albertsons offer excellent bang for your buck.

2 Top Value Stocks to Buy in May

Bausch (BHC) delivered earnings and revenue surprises of 10.64% and -2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Beats Q1 Earnings Estimates

Shares of Bausch Health Cos. Inc. were down 2.3% in premarket trading on Tuesday after the company said it faced continued pressure on sales from the COVID-19 pandemic into the first quarter of this year.

Bausch reports a $610 million loss in the first quarter of the year

LAVAL, Quebec, May 4, 2021 /PRNewswire/ --  First-Quarter 2021 Financial Results Revenues of $2.027 Billion GAAP Net Loss of $610 Million Adjusted EBITDA (non-GAAP) 1 of $852 Million GAAP Cash Generated from Operations of $443 Million Company Continues to Make Progress on Planned Separation of Eye Health Business Announces Leadership Team of Bausch + Lomb Now Operates in Five Reportable Segments Reaffirmed 2021 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its first-quarter 2021 financial results. "Bausch Health entered 2021 with strong momentum as our recovery from the COVID-19 pandemic continues.

News for Bausch Health Companies Inc Stock (BHC)